ReNeuron Group (AIM: RENE)

Last close As at 29/11/2024

3.38

0.00 (0.00%)

Market capitalisation

2m

ReNeuron is a UK biotech company developing allogeneic cell therapies. The first pivotal Phase IIb trial for CTX neural stem cells for chronic stroke disability is underway. Human retinal progenitor cells (hRPCs) are also being studied for RP (in Phase I/IIa).

Latest Insights

View More
ReNeuron-Group_resized

Further insights

insight

Healthcare

Stem cells

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free